Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ALDA to purchase manufacturing firm Seavan Health & Beauty Partnership
The proposed acquisition is expected to allow ALDA to manufacture its own T36 products, to continue the manufacture of SHBP’s own related product lines, which it will retain,
The proposed acquisition is expected to allow ALDA to manufacture its own T36 products, to continue the manufacture of SHBP’s own related product lines, which it will retain,
Gemcitabine HCI for Injection, the generic version of Gemcitabine HCI, was launched pursuant to a commercialization, manufacture and supply agreement signed by AstraZeneca and Taj Pharmaceuticals, indiacompanynews.com reported.
The agreement makes Partek Genomics Suite available through Life Technologies as a featured solution for analyzing data generated by Life Technologies’ next-generation sequencing (NGS) devices. Partek Genomics Suite
The certification was subject to the successful completion of AIFA audit of AMRI’s sterile fill and finish facility in Burlington, MA. This approval specifically applies to laboratories and
The companies will collaborate to advance-to-market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer. Debiopharm will shoulder full responsibility for the development and commercialization of
MOR103 is implicated in a number of inflammatory and other conditions including rheumatoid arthritis (RA) and multiple sclerosis (MS). The HuCAL-derived, fully human antibody is currently being tested
According to American Regent, potassium phosphates injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, belonging to lot number 48 is being
Bayer had initiated patient enrolment for a randomised, double-blind, placebo-controlled Phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with
The new investigational regimen, termed as 572-Trii, will combine the investigational integrase inhibitor S/GSK1349572 (‘572) and ViiV Healthcare’s combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa/Epzicom (ABC/3TC). The multi-centre,
Subsequently, Galapagos has regained worldwide rights for all assets developed in its strategic alliances with Merck & Co, through an affiliate. Merck will make a payment of EUR12m